RxDoctor Payments DataLook up a doctor →

Helena Rodbard

Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1346260841

Payments from drug & device makers

$2,377,698in general payments, 2019–2025

Across 1,393 payments — averaging $1706.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.5M
  • Novo Nordisk AS$359K
  • Lilly USA, LLC$173K
  • Sanofi-aventis U.S. LLC$75K
  • Merck$46K
  • Novo Nordisk$41K
  • plus $137K from 20 others
$133,328in research payments, 2019–2025

Across 34 payments — averaging $3921.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$102K
  • Eli Lilly$21K
  • Bayer$6K
  • Sanofi-aventis U.S. LLC$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,377,698 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland

Other endocrinology, diabetes & metabolism in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →